A somatostatin receptor subtype-3 (SST3) peptide agonist shows antitumor effects in experimental models of nonfunctioning pituitary tumors

JUAN SOLIVERA VELAJUSTO PASTOR CASTAÑO FUENTESMANUEL DAVID GAHETE ORTIZRAUL MIGUEL LUQUE HUERTASALEJANDRO IBÁÑEZ COSTA2026-01-292026-01-29202010.1158/1078-0432.CCR-19-21542-s2.0-85079421938https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/31362Cancer ResearchOncologyCancer ResearchOncologyA somatostatin receptor subtype-3 (SST3) peptide agonist shows antitumor effects in experimental models of nonfunctioning pituitary tumorsresearch article